IDEXX Laboratories (NASDAQ:IDXX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $600.83, a high estimate of $700.00, and a low estimate of $510.00. This upward trend is evident, with the current average reflecting a 15.36% increase from the previous average price target of $520.83.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive IDEXX Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Westenberg | Piper Sandler | Raises | Neutral | $700.00 | $510.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $675.00 | $550.00 |
| Daniel Clark | Leerink Partners | Raises | Outperform | $600.00 | $580.00 |
| Jonathan Block | Stifel | Raises | Hold | $540.00 | $510.00 |
| Daniel Clark | Leerink Partners | Raises | Outperform | $580.00 | $515.00 |
| Jonathan Block | Stifel | Raises | Hold | $510.00 | $460.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IDEXX Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IDEXX Laboratories compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of IDEXX Laboratories's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of IDEXX Laboratories's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on IDEXX Laboratories analyst ratings.
Delving into IDEXX Laboratories's Background
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
A Deep Dive into IDEXX Laboratories's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining IDEXX Laboratories's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.55% as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 26.5%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 20.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IDEXX Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.98% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.85.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
